keyword
MENU ▼
Read by QxMD icon Read
search

Apheresis stem cells

keyword
https://www.readbyqxmd.com/read/28417344/biotherapy-in-inflammatory-diseases-of-the-cns-current-knowledge-and-applications
#1
REVIEW
Nicolas Collongues, Laure Michel, Jérôme de Seze
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders...
May 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28411174/evaluation-of-hematopoietic-stem-cell-mobilization-rates-with-early-plerixafor-administration-time-for-adult-stem-cell-transplantation
#2
Jessica T Stover, J Ryan Shaw, Maragatha Kuchibhatla, Mitchell E Horwitz, Ashley M Engemann
The addition of plerixafor to high-dose colony stimulating growth factor has been shown to improve stem cell mobilization rates in autologous transplant patients with multiple myeloma and non-Hodgkin's lymphoma. This study evaluates the change in administration time of plerixafor to determine if cell mobilization rates are similar between the FDA approved administration time of 11 hours prior to apheresis and an earlier administration time of 16 hours prior to apheresis. Medical records of patient ≥ 18 years of age undergoing autologous stem cell transplantation requiring the use of plerixafor after at least four days of G-CSF therapy to complete stem cell mobilization from 1 January 2010 through 30 September 2014 were retrospectively reviewed...
April 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28392150/factual-reflections-and-recommendations-on-extracorporeal-photopheresis-in-pediatrics
#3
REVIEW
Irena Sniecinski, Jerard Seghatchian
One of the biggest challenges in evaluating available literature on extracorporeal photopheresis (ECP) practices in pediatric patients is the marked heterogeneity of approaches to the patient evaluation, procedural aspects and apheresis product analysis. These issues are most relevant in ECP management in children with graft versus host disease (GVHD) after hematopoietic stem cell transplantation. Extracorporeal photopheresis in pediatric patients is considered relatively safe with few adverse effects reported from retrospective or observational studies...
March 22, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28370131/use-of-allogeneic-apheresis-stem-cell-products-as-an-interlaboratory-proficiency-challenge
#4
Laura Cooling, Kelly Roxbury, Sandra Hoffmann, Joan DeBusscher, Usha Kota, Steven Goldstein, Robertson Davenport
BACKGROUND: AABB Standards requires that laboratories participate in a proficiency test (PT) program for critical analytes. Institutions can purchase commercial PT materials; however, PT can also be performed through interlaboratory exchange. We investigated the utility of allogeneic hematopoietic progenitor cell apheresis (HPC-A) products as an interlaboratory PT challenge for total nucleated cell count (TNC) and CD34 assessment. STUDY DESIGN AND METHODS: Three-year retrospective and comparative review of unrelated allogeneic HPC-A products received by the University of Michigan between January 2011 and December 2013...
March 28, 2017: Transfusion
https://www.readbyqxmd.com/read/28331129/impact-of-hematopoietic-progenitor-cell-count-as-an-indicator-for-optimal-timing-of-peripheral-stem-cell-harvest-in-clinical-practice
#5
Hiroaki Tanaka, Akihiro Ishii, Yasumasa Sugita, Ryo Shimizu, Fumi Sato, Yukie Sakuma, Rie Iwai, Shinichiro Kakuta
For optimizing CD34+ cell collection, appropriately timing peripheral blood stem cell harvest (PBSCH) initiation is crucial. Automatic cell analyzers with the immature myeloid information channel provide hematopoietic progenitor cell (HPC) count, a surrogate marker of CD34+ cells, which can be obtained within a few minutes without requiring monoclonal antibodies. The final decision on PBSCH initiation can be made using the HPC count obtained on the morning of the harvest day. Herein, we evaluated the impact of the HPC count as an indicator for the optimal timing of PBSCH in clinical practice over 9 years...
2017: Journal of Clinical and Experimental Hematopathology: JCEH
https://www.readbyqxmd.com/read/28319139/identification-of-cell-morphology-parameters-from-automatic-hematology-analyzers-to-predict-the-peripheral-blood-cd34-positive-cell-count-after-mobilization
#6
Saeam Shin, Sung Ran Cho, Sinyoung Kim, Jong Rak Choi, Kyung-A Lee
Optimal timing of apheresis initiation is important for maximizing the hematopoietic stem cell (HSC) yield. This study aimed to identify useful parameters from automatic hematology analyzers for predicting the peripheral blood CD34+ cell count after mobilization. We prospectively enrolled 53 healthy donors and 72 patients, and evaluated 43 cell morphology parameters from Unicel DxH800 (Beckman Coulter, USA) and Advia 2120i (Siemens Healthcare Diagnostics, USA). The correlation of each parameter with the CD34+ cell count in pre-apheresis blood samples was analyzed...
2017: PloS One
https://www.readbyqxmd.com/read/28301051/adverse-events-of-cryopreserved-hematopoietic-stem-cell-infusions-in-adults-a-single-center-observational-study
#7
Zaher K Otrock, Diane S Sempek, Sherry Carey, Brenda J Grossman
BACKGROUND: Autologous hematopoietic stem cell (HSC) transplantation has been used for almost three decades for the management of malignant hematologic diseases and some solid tumors. Dimethyl sulfoxide (DMSO) is used as a cryoprotective agent for hematopoietic progenitor cells (HPCs) collected by apheresis (HPC-A). We evaluated the factors contributing to the occurrence of adverse events (AEs) of cryopreserved HPC-A infusion. STUDY DESIGN AND METHODS: Between January 2009 and June 2014, a total of 1269 (1191 patients) consecutive HPC-A infusions were given to adult patients undergoing autologous HSC transplantation at Barnes-Jewish Hospital...
March 16, 2017: Transfusion
https://www.readbyqxmd.com/read/28296283/effects-of-transendocardial-cd34-cell-transplantation-on-diastolic-parameters-in-patients-with-nonischemic-dilated-cardiomyopathy
#8
Mojca Bervar, Mirta Kozelj, Gregor Poglajen, Matjaz Sever, Gregor Zemljic, Sabina Frljak, Marko Cukjati, Peter Cernelc, François Haddad, Bojan Vrtovec
We sought to evaluate the physiological background and the effects of CD34(+) cell transplantation on diastolic parameters in nonischemic dilated cardiomyopathy patients (DCM). We enrolled 38 DCM patients with NYHA class III and LVEF <40% who underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by G-CSF, collected via apheresis, and injected transendocardially in the areas of myocardial hibernation. Patients were followed for 1 year. At baseline, estimated filling pressures were significantly elevated (E/e'≥15) in 18 patients (Group A), and moderately elevated (E/e'<15) in 20 patients (Group B)...
March 11, 2017: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/28292947/mobilization-of-allogeneic-peripheral-blood-stem-cell-donors-with-intravenous-plerixafor-mobilizes-a-unique-graft
#9
Mark A Schroeder, Michael P Rettig, Sandra Lopez, Stephanie Christ, Mark Fiala, William Eades, Fazia A Mir, Jin Shao, Kyle McFarland, Kathryn Trinkaus, William Shannon, Elena Deych, Jinsheng Yu, Ravi Vij, Keith Stockerl-Goldstein, Amanda F Cashen, Geoffery L Uy, Camille N Abboud, Peter Westervelt, John F DiPersio
A single subcutaneous (SC) injection of plerixafor results in rapid mobilization of hematopoietic progenitors but fails to mobilize 33% of normal allogeneic sibling donors in one apheresis. We hypothesized that changing the route of administration of plerixafor from SC to intravenous (IV) may overcome the low stem cell yields and allow collection in one day. A phase I trial followed by a phase II efficacy trial was conducted in allogeneic sibling donors. The optimal dose of IV plerixafor was determined to be 0...
March 14, 2017: Blood
https://www.readbyqxmd.com/read/28286619/optimizing-stem-cells-mobilization-strategies-to-ameliorate-patient-outcomes-a-review-of-guide-lines-and-recommendations
#10
REVIEW
Saeed Mohammadi, Ashraf Malek Mohammadi, Mohsen Nikbakht, Amir Hossein Norooznezhad, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Peripheral blood stem cell transplantation (PBSCT) is an effective treatment for hematological malignancies. Mobilization of peripheral blood progenitor cells performs in different ways among transplantation centers. Forceful mobilization schedules are comprised of growth factor alone, chemotherapy along with growth factor and also, a newly combination of novel agent such as plerixafor with any approach. With the appearance of numerous modifications in stem cell mobilization field over the past decade and advent of novel stem cell mobilization techniques, it seems to be necessary to review recent publications about stem cell mobilization strategies to respond above cited issues...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28281429/single-centre-experience-of-allogeneic-haemopoietic-stem-cell-transplant-in-paediatric-patients-in-cape-town-south-africa
#11
A Van Eyssen, N Novitsky, P De Wit, T Schlaphoff, V Thomas, D Pillay, M Hendricks, A Davidson
BACKGROUND: Allogeneic haemopoietic stem cell transplant (Allo-HSCT) is a specialised and costly intervention, associated with significant morbidity and mortality. It is used to treat a broad range of paediatric conditions. South Africa (SA) is an upper middle-income country with limitations on healthcare spending. The role of paediatric Allo-HSCT in this setting is reviewed. OBJECTIVES: To review paediatric patients who underwent Allo-HSCT at the Groote Schuur Hospital/University of Cape Town Private Academic Hospital transplant unit in Cape Town, South Africa, and received post-transplant care at Red Cross War Memorial Children's Hospital, over the period January 2006 - December 2014 in respect of indications for the transplant, donor sources, conditioning regimens, treatment-related morbidity and overall survival (OS)...
February 27, 2017: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/28271674/comparison-of-six-different-cryoprotective-agents-used-for-deep-freezing-and-storage-of-cd34-cells-derived-from-cord-blood-and-peripheral-blood-stem-cell-concentrates
#12
Julian Strobel, Friederike Hohensee, Piotr Kuta, Reinhold Eckstein, Juergen Zingsem
BACKGROUND: For cryopreservation of stem cells, a cryoprotective agent is essential. Dimethyl sulfoxide is commonly used, but has deleterious effects on cell vitality in the warmth and for the recipients of stem cells. The aim of the study was to reduce DMSO and find one cryoprotective solution suitable for stem cells of different origin. Materials: Small volumes of both stem cell apheresis products and cord blood derived stem cells were frozen using six different cryoprotective solutions...
March 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28260456/intrathecal-injection-of-peripherally-mobilized-blood-stem-cells-to-treat-multiple-sclerosis
#13
Abdul Majeed Hammadi, Fizel Abbas Al-Himyari
In this study, we analyzed 70 patients with worseningmultiple sclerosis despite pharmacologic treatment who were treated with several intrathecal injections of peripheral blood cells harvested by apheresis after granulocyte-colony stimulating factor treatment. Thirty-seven patients (52%) had a reduction of Expanded Disability Status Scale score; 10 patients had relapses, although these were milder than usual and more easily controlled by corticosteroids. Because mesenchymal cells increase in the peripheral blood after granulocyte-colony stimulating factor stimulation, a peripheral blood harvest seems easier and less costly than mesenchymal cell cultivation before injection...
February 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28185276/patient-age-and-number-of-apheresis-days-may-predict-development-of-secondary-myelodysplastic-syndrome-and-acute-myelogenous-leukemia-after-high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-lymphoma
#14
Isabell Ge, Rima M Saliba, Farzaneh Maadani, Uday R Popat, Muzaffar H Qazilbash, Sai Ravi Pingali, Nina Shah, Sairah Ahmed, Qaiser Bashir, Yago Nieto, Richard E Champlin, Chitra Hosing
BACKGROUND: The goal of our study was to find predictors for the development of secondary myelodysplastic syndrome or acute myelogenous leukemia (s-MDS/AML) in patients with relapsed or refractory lymphoma who received high-dose chemotherapy and autologous stem cell transplantation (ASCT). STUDY DESIGN AND METHODS: We conducted a retrospective review of 295 patients with relapsed or refractory lymphoma who had undergone their first stem cell collection and ASCT...
February 10, 2017: Transfusion
https://www.readbyqxmd.com/read/28164682/comparison-of-simultaneous-cd34-and-cd3-quantification-with-a-modified-stem-cell-enumeration-kit-on-two-different-flow-cytometers
#15
Julian Strobel, Barbara Hauck-Dlimi, Volker Weisbach, Reinhold Eckstein, Juergen Zingsem, Erwin Strasser
BACKGROUND: Quantification of CD34+ cells in peripheral blood stem cell apheresis is normally performed by single platform flow cytometric measurements according to the ISHAGE protocol. Peripheral blood stem cell concentrates (PBSC) produced by apheresis normally contain many T cells. Those T cells can be used for production of donor lymphocyte infusion doses, if abundant amounts of CD34+ cells have been collected. Therefore, it is of interest to know both the CD3+ and the CD34+ cell count of allogeneic PBSC...
November 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28162978/distribution-of-indications-and-procedures-within-the-framework-of-centers-participating-in-the-waa-apheresis-registry
#16
REVIEW
B Stegmayr, M Mörtzell Henriksson, E Newman, V Witt, K Derfler, G Leitner, S Eloot, A Dhondt, D Deeren, G Rock, J Ptak, M Blaha, M Lanska, Z Gasova, Z Bhuiyan-Ludvikova, R Hrdlickova, W Ramlow, H Prophet, G Liumbruno, E Mori, A Griskevicius, J Audzijoniene, H Vrielink, E Rombout-Sestrienkova, A Aandahl, A Sikole, J Tomaz, K Lalic, I Bojanic, V Strineholm, B Brink, G Berlin, J Dykes, F Toss, T Nilsson, F Knutson, B Ramsauer, A Wahlstrom
The WAA apheresis registry was established in 2003 and an increasing number of centers have since then included their experience and data of their procedures. The registry now contains data of more than 74,000 apheresis procedures in more than 10,000 patients. This report shows that the indications for apheresis procedures are changing towards more oncological diagnoses and stem cell collections from patients and donors and less therapeutic apheresis procedures. In centers that continue to register, the total extent of apheresis procedures and patients treated have expanded during the latest years...
February 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28139098/predictors-for-successful-pbsc-collection-on-the-fourth-day-of-g-csf-induced-mobilization-in-allogeneic-stem-cell-donors
#17
Anja van Oostrum, Jaap Jan Zwaginga, Sandra Croockewit, Jacqueline Overdevest, Mirjam Fechter, Bart Ruiterkamp, Anneke Brand, Tanja Netelenbos
Peripheral blood stem cells (PBSCs) used for allogeneic transplantation are collected by apheresis after pre-treatment of donors with G-CSF. Using modern apheresis devices stem cells can be collected more efficiently. It was studied whether collection on the 4th instead of the 5th day after initiation of G-CSF treatment might be feasible. Stem cell yields that could have been collected on day 4 were calculated in two cohorts treated with 10 µg/kg G-CSF once daily (n = 106, cohort I) or 5 µg/kg twice daily schedule (n = 85, cohort II)...
January 31, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28115876/management-of-psychiatric-complications-in-unrelated-donor-before-unrelated-peripheral-hematopoietic-stem-cell-collections
#18
Olivier Hequet, Valerie Mialou, Francoise Audat, Eric Wattel, Valerie Chapel, Damiela Revesz, Jean-Piere Jouet, Brigitte Fisseaux, Mohamed Saoud, Mauricette Michallet
Allogeneic hematopoietic stem cell transplantation can efficiently treat patients with severe hematological diseases. A human leukocyte antigen-compatible donor is required for performing transplantation. The occurrence of unexpected acute severe diseases in a donor can compromise the feasibility of allogeneic hematopoietic stem cell transplantation. However, when a severe health problem occurs in a donor while the recipient has already received a conditioning regimen, hematologists have to find the best solutions for the recipient, while the team in charge of the donor has to find the best medical solutions for the donor...
2017: Journal of Blood Medicine
https://www.readbyqxmd.com/read/28109298/neuroregenerative-potential-of-intravenous-g-csf-and-autologous-peripheral-blood-stem-cells-in-children-with-cerebral-palsy-a-randomized-double-blind-cross-over-study
#19
Wee-Jin Rah, Young-Ho Lee, Jin-Hwa Moon, Hyun-Ju Jun, Hye-Ryeong Kang, Hani Koh, Hye Jung Eom, Ji Young Lee, Young Jun Lee, Ji Young Kim, Yun-Young Choi, Kyeongil Park, Mi Jung Kim, Seung-Hyun Kim
OBJECTIVE: We performed a randomized, double-blind, cross-over study to assess the neuroregenerative potential of intravenous granulocyte colony-stimulating factor (G-CSF) followed by infusion of mobilized peripheral blood mononuclear cells (mPBMCs) in children with cerebral palsy (CP). METHODS: Children with non-severe CP were enrolled in this study. G-CSF was administered for 5 days, then mPBMCs were collected by apheresis and cryopreserved. One month later (M1), recipients were randomized to receive either mPBMCs or a placebo infusion, and these treatment groups were switched at 7 months (M7) and observed for another 6 months (M13)...
January 21, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28089409/the-italian-registry-of-therapeutic-apheresis-2015
#20
REVIEW
Giustina De Silvestro
Data collection on apheresis activities in Italy throughout 2015 including techniques, clinical indications and adverse effects was performed by means of a SidEM model questionnaire (aggregate data). These data provided by 67 Apheresis Units from 17 Italian regions, albeit rough, are sufficiently informative, mainly in comparison with previous surveys on these statistics. PEx has been the most frequent technique for plasma removal/treatment (11787 procedures) followed by LDL-apheresis (927 procedures). ECP/photopheresis has been the most frequent cytapheresis procedure: 6,606 session, mainlyby using the off-line technique...
February 2017: Transfusion and Apheresis Science
keyword
keyword
41980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"